An open label randomized comparison of mefloquine–artesunate as separate tablets vs. a new co‐formulated combination for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand
暂无分享,去创建一个
F. Nosten | P. Olliaro | K. Stepniewska | E. Ashley | N. White | P. Singhasivanon | R. McGready | K. Lwin. | M. Barends | W. Taylor | S. Proux | W. Leowattana | K. Thwai | L. Phaiphun | W. H. Simon | Nantawan Wangseang | Wimon Nawamaneerat
[1] F. Nosten,et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] F. Nosten,et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. , 2004, The Journal of infectious diseases.
[3] Richard N. Price,et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.
[4] H. Webster,et al. The epidemiology of malaria in a Karen population on the western border of Thailand. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[5] N. White,et al. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[6] F. Nosten,et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. , 1999, The American journal of tropical medicine and hygiene.